U.S. flag

An official website of the United States government, Department of Justice.

Desomorphine Screening Using Commercial Enzyme-Linked Immunosorbent Assays

NCJ Number
252452
Date Published
June 2017
Length
6 pages
Author(s)
Jessia Winborn; Sarah Kerrigan
Agencies
NIJ-Sponsored
Publication Type
Research (Applied/Empirical), Report (Study/Research), Report (Grant Sponsored), Program/Project Description
Grant Number(s)
2015-R2-CX-0031
Annotation
This report describes the cross-reactivity of desomorphine, using the following six commercially available enzyme-linked immunosorbent assays: Immunalysis Opiates Direct ELISA; Immunalysis Oxycodone/Oxymorphone Direct ELISA; Randox Opiate ELISA; OraSure Technologies OTI Opiate Micro-plate EIA; Neogen Opiate Group ELISA; and Neogen Oxycodone/Oxymorphone ELISA).
Abstract
Desomorphine ("Krokodil") is a semi-synthetic opioid that has drawn attention as a recreational drug, particularly in Russia, neighboring former Soviet Republics, and Eastern and Central Europe. It has no accepted medicinal uses and is currently a schedule I drug in the United States. In clandestine environments, desomorphine is synthesized from codeine using red phosphorous, hydroiodic acid and gasoline. Residual starting materials in illicit preparations have been associated with severe dermatological effects and extensive tissue necrosis. Desomorphine is not well studied, and there are limited reports concerning its pharmacology or detection in biological matrices. Immunoassays are widely relied upon for both antemortem and postmortem toxicology screening. Although desomorphine is an opioid of the phenanthrene-type, its ability to bind to conventional opioid antibodies has not been described. The current study found that cross-reactivites were highly variable between assays, ranging from 77 to <2.5 percent. In general, assays directed towards morphine produced greater cross-reactivity with desomorphine than those directed towards oxycodone. The Immunalysis Opiates Direct ELISA produced the greatest cross-reactivity, although several of the assays evaluated produced cross-reactivity of a sufficient magnitude to be effective for desomorphine screening. 4 figures, 2 tables, and 16 references (Publisher abstract modified)
Date Created: July 20, 2021